Complete Filing Data
Zura Bio Ltd reported Net Income Loss of -$68.65 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Zura Bio Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income * | -$68.7M | -$52.4M | -$60.4M | -$25.7M |
| Operating Income Loss | -$75.2M | -$55.2M | -$62.6M | -$27.2M |
| General And Administrative Expense | $33.2M | $30.8M | $18.6M | $3.5M |
| Nonoperating Income Expense | $6.6M | $2.8M | $2.1M | $6.2M |
| Research And Development Expense | $42.1M | $24.4M | $44.0M | $23.7M |
| Operating Expenses | $75.2M | $55.2M | $62.6M | $27.2M |
| Net Income Loss Available To Common Stockholders Basic | -$99.4M | -$45.4M | -$69.2M | -$32.4M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$68.7M | -$52.4M | -$60.6M | -$27.3M |
| Other Nonoperating Income Expense | $2.1M | -$171.0K | ||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$52.4M | -$60.6M | -$27.3M | |
| Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party | $381.1K | |||
| Net Income Loss Attributable To Redeemable Noncontrolling Interest | -$203.0K | -$1.6M | ||
| General And Administrative Expenses Paid By Related Party Under Promissory Note | ||||
| Research And Development Expense On Acquired License | $27.4M | $21.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$18.0M | -$16.0M | -$17.4M | -$20.7M | -$10.3M | -$7.7M | -$8.3M | -$34.0M | -$9.6M | -$1.1M | -$925.0K | -$7.8M | $5.8M | -$19.1K | -$33.0K |
| Operating Income Loss | -$19.5M | -$18.1M | -$19.3M | -$19.3M | -$11.8M | -$8.4M | -$10.2M | -$33.9M | -$7.7M | -$1.1M | -$927.0K | -$7.8M | -$321.9K | -$19.1K | -$33.0K |
| General And Administrative Expense | $7.6M | $9.4M | $8.8M | $13.3M | $6.2M | $4.8M | $6.2M | $5.7M | $2.8M | $653.0K | $842.0K | $319.0K | $242.0K | $19.1K | $33.0K |
| Nonoperating Income Expense | $1.5M | $2.1M | $1.8M | -$1.4M | $1.4M | $632.0K | $1.9M | -$120.0K | -$2.1M | $1.0M | $3.3M | $560.2K | $6.1M | $0.00 | |
| Research And Development Expense | $11.9M | $8.7M | $10.5M | $6.0M | $5.5M | $3.6M | $4.0M | $28.2M | $4.9M | $415.0K | $85.0K | $7.5M | |||
| Operating Expenses | $19.5M | $18.1M | $19.3M | $19.3M | $11.8M | $8.4M | $10.2M | $33.9M | $7.7M | $1.1M | $927.0K | $7.8M | |||
| Net Income Loss Available To Common Stockholders Basic | -$20.0M | -$16.0M | -$17.4M | -$22.9M | -$12.7M | -$730.0K | -$8.3M | -$44.9M | -$9.8M | -$1.1M | -$925.0K | -$7.8M | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$18.0M | -$16.0M | -$17.4M | -$20.7M | -$10.3M | -$7.7M | -$8.3M | -$34.0M | -$9.8M | -$1.1M | -$925.0K | -$7.8M | |||
| Other Nonoperating Income Expense | -$47.0K | $352.0K | -$5.0K | $22.0K | $2.0K | $23.0K | -$4.0K | $7.0K | -$10.0K | -$34.0K | $2.0K | ||||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$20.7M | -$10.3M | -$7.7M | -$8.3M | -$34.0M | -$9.8M | -$1.1M | -$925.0K | -$7.8M | ||||||
| Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party | $51.7K | $198.0K | $90.0K | $79.9K | $0.00 | ||||||||||
| Net Income Loss Attributable To Redeemable Noncontrolling Interest | -$203.0K | ||||||||||||||
| General And Administrative Expenses Paid By Related Party Under Promissory Note | -$8.0K | $51.0K | $50.0K | ||||||||||||
| Research And Development Expense On Acquired License |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity * | $101.5M | $146.8M | $59.3M | -$32.1M | -$9.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $109.4M | $176.5M | $99.8M | $1.6M | $729.2K |
| Retained Earnings Accumulated Deficit | -$224.5M | -$155.9M | -$103.5M | -$32.1M | -$9.2M |
| Liabilities And Stockholders Equity | $113.9M | $179.5M | $100.8M | $5.3M | $140.6M |
| Liabilities | $12.4M | $19.5M | $21.3M | $14.8M | $10.4M |
| Assets Current | $112.3M | $178.7M | $100.8M | $1.8M | $1.2M |
| Assets | $113.9M | $179.5M | $100.8M | $5.3M | $140.6M |
| Liabilities Current | $12.4M | $19.5M | $20.3M | $14.8M | $272.3K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$67.1M | $76.7M | $98.2M | $1.6M | |
| Temporary Equity Accretion To Redemption Value Adjustment | -$4.9M | $7.2M | $6.7M | $19.2M | |
| Accounts Payable And Accrued Liabilities Current | $12.4M | $19.5M | $20.3M | $4.4M | |
| Cash And Cash Equivalents At Carrying Value | $109.4M | $176.5M | $99.8M | $13.8K | $729.2K |
| Redeemable Noncontrolling Interest Equity Carrying Amount | $11.7M | $18.7M | $10.0M | ||
| Minority Interest | $1.5M | $1.5M | $0.00 | ||
| Common Stock Value | $7.0K | $7.0K | $4.0K | ||
| Gain Loss On Investments | $2.1M | ||||
| Temporary Equity Carrying Amount Attributable To Parent | $12.5M | $139.4M | |||
| Cash | $109.4M | $176.5M | $99.8M | $13.8K | $729.2K |
| Payment Of Deferred Transaction Costs | $1.2M | $2.8M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$715.4K | ||||
| Accrued Liabilities Current | $1.1M | $199.6K | |||
| Accounts Payable Current | $282.1K | $69.9K | |||
| Fair Value Adjustment Of Note Payable | $2.2M | $156.0K | |||
| Deferred Underwriting Compensation Noncurrent | $4.0M | $4.0M | |||
| Assets Held In Trust Noncurrent | $141.5M | $139.4M | |||
| Transaction Costs Include In Accounts Payable | $655.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $108.2M | $125.9M | $138.2M | $153.0M | $156.5M | $61.0M | $63.2M | $68.9M | $27.9M | -$7.1M | -$6.9M | -$7.8M | -$10.3M | -$27.2K | -$8.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $139.0M | $154.5M | $170.6M | $188.2M | $188.4M | $89.8M | $103.9M | $112.8M | $44.0M | $3.0M | $4.4M | $4.7M | $986.6K | $25.0K | $25.0K |
| Retained Earnings Accumulated Deficit | -$207.4M | -$189.3M | -$173.3M | -$142.3M | -$121.6M | -$111.2M | -$95.0M | -$86.8M | -$41.9M | -$7.1M | -$6.9M | -$9.0M | -$10.3M | -$52.2K | -$33.0K |
| Liabilities And Stockholders Equity | $143.9M | $157.8M | $172.5M | $189.1M | $189.5M | $90.5M | $104.6M | $113.3M | $44.4M | $140.5M | $140.0M | $140.3M | $140.9M | $164.8K | $95.6K |
| Liabilities | $25.5M | $18.7M | $21.1M | $18.2M | $17.4M | $16.3M | $19.0M | $22.0M | $6.5M | $7.4M | $7.4M | $9.9M | $11.8M | $191.9K | $103.6K |
| Assets Current | $142.3M | $157.0M | $171.7M | $189.0M | $189.5M | $90.5M | $104.6M | $113.3M | $44.4M | $196.7K | $436.6K | $837.0K | $1.5M | $25.0K | $25.0K |
| Assets | $143.9M | $157.8M | $172.5M | $189.1M | $189.5M | $90.5M | $104.6M | $113.3M | $44.4M | $140.5M | $140.0M | $140.3M | $140.9M | $164.8K | $95.6K |
| Liabilities Current | $25.5M | $18.7M | $21.1M | $18.2M | $15.1M | $14.7M | $17.0M | $19.9M | $5.0M | $1.3M | $1.0M | $369.4K | $133.2K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$5.9M | -$10.0M | $42.4M | $4.7M | |||||||||||
| Temporary Equity Accretion To Redemption Value Adjustment | $2.8M | $2.2M | $2.3M | $203.0K | $20.8M | ||||||||||
| Accounts Payable And Accrued Liabilities Current | $25.5M | $18.7M | $21.1M | $18.2M | $15.1M | $14.7M | $17.0M | $19.9M | $5.0M | ||||||
| Cash And Cash Equivalents At Carrying Value | $139.0M | $154.5M | $170.6M | $188.2M | $74.5K | $220.7K | $514.6K | $986.6K | $25.0K | $25.0K | |||||
| Redeemable Noncontrolling Interest Equity Carrying Amount | $8.7M | $11.7M | $11.7M | $16.2M | $14.0M | $11.7M | $20.9M | $20.9M | |||||||
| Minority Interest | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M | |||||||
| Common Stock Value | $7.0K | $6.0K | $7.0K | $7.0K | $6.0K | $4.0K | $4.0K | $4.0K | $3.0K | ||||||
| Gain Loss On Investments | $686.5K | $181.2K | $16.3K | $6.9K | $0.00 | ||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $140.2M | $139.5M | $139.4M | $139.4M | |||||||||||
| Cash | $139.0M | $154.5M | $170.6M | $188.2M | $74.5K | $220.7K | $514.6K | $986.6K | $25.0K | $25.0K | |||||
| Payment Of Deferred Transaction Costs | $1.0M | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$214.6K | $25.0K | $25.0K | ||||||||||||
| Accrued Liabilities Current | $836.2K | $728.9K | $175.1K | $103.3K | $2.9K | $4.9K | |||||||||
| Accounts Payable Current | $159.2K | $30.0K | $194.3K | $29.9K | $71.6K | $48.7K | |||||||||
| Fair Value Adjustment Of Note Payable | $2.2M | ||||||||||||||
| Deferred Underwriting Compensation Noncurrent | $4.0M | $4.0M | $4.0M | $4.0M | |||||||||||
| Assets Held In Trust Noncurrent | $140.3M | $139.6M | $139.4M | $139.4M | |||||||||||
| Transaction Costs Include In Accounts Payable | $154.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$64.8M | -$28.1M | -$15.1M | -$1.2M |
| Net Cash Provided By Used In Financing Activities | -$2.2M | $109.8M | $121.3M | $14.8M |
| Net Cash Provided By Used In Investing Activities | -$113.0K | -$5.1M | -$8.0M | -$12.0M |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$2.2M | $4.2M | $5.9M | $3.8M |
| Share Based Compensation | $12.3M | $16.8M | $7.5M | $334.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $657.0K | $1.2M | $828.0K | $209.0K |
| Payments To Acquire In Process Research And Development | $5.0M | $8.0M | $12.0M | |
| Proceeds From Issuance Of Common Stock | $56.7M | |||
| Increase Decrease In Accrued Liabilities | $912.1K | |||
| Increase Decrease In Accounts Payable | $212.3K | |||
| Proceeds From Issuance Of Private Placement | $59.7M | |||
| Payments Of Stock Issuance Costs | $626.0K | $4.2M | ||
| Increase Decrease In Prepaid Expense | -$403.2K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q2 2023 | Q1 2023 | Q1 2022 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$11.1M | -$5.0M | -$3.3M | -$280.0K | $25.0K | $25.0K | |
| Net Cash Provided By Used In Financing Activities | $5.2M | $45.7M | $10.0M | ||||
| Net Cash Provided By Used In Investing Activities | -$49.0K | -$5.0M | -$5.0M | ||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $1.6M | -$607.0K | $455.0K | $39.0K | |||
| Share Based Compensation | $3.6M | $2.4M | $180.0K | ||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.1M | -$380.0K | $213.0K | ||||
| Payments To Acquire In Process Research And Development | $5.0M | $5.0M | |||||
| Proceeds From Issuance Of Common Stock | $56.7M | ||||||
| Increase Decrease In Accrued Liabilities | -$24.4K | $2.9K | $4.9K | ||||
| Increase Decrease In Accounts Payable | $124.4K | $23.3K | $3.1K | ||||
| Proceeds From Issuance Of Private Placement | |||||||
| Payments Of Stock Issuance Costs | $100.0K | ||||||
| Increase Decrease In Prepaid Expense | -$105.7K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Diluted EPS * | -$1.06 | -$0.60 | -$2.09 | -$141.97 | |
| Preferred Stock Shares Authorized | 1.0M | 0.00 | 1.0M | ||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | ||
| Weighted Average Number Of Shares Outstanding Basic | 94.2M | 75.1M | 33.1M | 228.1K | |
| Weighted Average Number Of Diluted Shares Outstanding | 94.2M | 75.1M | 33.1M | 228.1K | |
| Earnings Per Share Basic | $-1.06 | $-0.60 | $-2.09 | $-141.97 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | ||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | ||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 1.9M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 73.7M | 65.3M | 43.6M | 279.7K | |
| Common Stock Shares Issued | 73.7M | 65.3M | 43.6M | 279.7K | |
| Temporary Equity Shares Outstanding | 0.00 | 13.5M | |||
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.21 | -$0.17 | -$0.19 | -$0.26 | -$0.17 | -$0.02 | -$0.18 | -$1.31 | -$2.76 | -$2.87 | -$9.54 | -$72.4K | -$0.01 | -$0.01 | |||
| Preferred Stock Shares Authorized | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 94.6M | 94.3M | 93.0M | 87.3M | 74.9M | 46.9M | 46.9M | 34.3M | 3.6M | 383.5K | 97.0K | 108.00 | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 94.6M | 94.3M | 93.0M | 87.3M | 74.9M | 46.9M | 46.9M | 34.3M | 3.6M | 383.5K | 97.0K | 108.00 | |||||
| Earnings Per Share Basic | $-0.21 | $-0.17 | $-0.19 | $-0.26 | $-0.17 | $-0.02 | $-0.18 | $-1.31 | $-2.76 | $-2.87 | $-9.54 | $-72,395.48 | |||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
| Common Stock Shares Outstanding | 65.0M | 62.1M | 68.4M | 65.3M | 63.7M | 43.6M | 43.1M | 43.1M | 27.1M | ||||||||
| Common Stock Shares Issued | 65.0M | 62.1M | 68.4M | 65.3M | 63.7M | 43.6M | 43.1M | 43.1M | 27.1M | ||||||||
| Temporary Equity Shares Outstanding | 0.00 | 0.00 | 0.00 | 13.8M | 13.8M | 13.8M | |||||||||||
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Investment Income Interest | $6.3M | $8.0M | $2.2M | $8.0K | |
| Fair Value Adjustment Of Warrants | $5.2M | -$724.0K | -$4.1M | ||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $12.3M | $16.8M | $13.1M | $334.0K | |
| Foreign Currency Transaction Gain Loss Before Tax | -$84.0K | $27.0K | $17.0K | -$23.0K | |
| Additional Paid In Capital | $326.1M | $302.7M | $162.8M | ||
| Exchange Ratio For Ordinary Shares Pursuant To Business Combination | 108.08 | 108.08 | 108.08 | ||
| Other Prepaid Expense Current | $209.0K | ||||
| Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares | 1.9M | 6.1M | |||
| Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent | 990.0K | ||||
| Prepaid Expense Current | $19.7K | $422.9K | |||
| Stock Issued During Period Value New Issues |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment Income Interest | $1.5M | $1.7M | $1.8M | $2.5M | $2.2M | $1.2M | $815.0K | $1.0K | $224.00 | $42.00 | $14.00 | $29.00 | $0.00 | |||
| Fair Value Adjustment Of Warrants | $3.9M | $768.0K | $606.0K | -$119.0K | $532.0K | -$177.0K | -$315.3K | -$3.2M | -$543.9K | -$8.6M | $0.00 | $0.00 | ||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.4M | $3.7M | $3.6M | $8.6M | $2.9M | $2.4M | $2.6M | $7.9M | $180.0K | $12.0K | $309.0K | |||||
| Foreign Currency Transaction Gain Loss Before Tax | -$24.0K | $23.0K | -$9.0K | |||||||||||||
| Additional Paid In Capital | $315.6M | $315.2M | $311.5M | $295.3M | $278.1M | $172.2M | $158.2M | $155.7M | $69.7M | $24.7K | $24.6K | |||||
| Exchange Ratio For Ordinary Shares Pursuant To Business Combination | 108.08 | 108.08 | 108.08 | 108.08 | ||||||||||||
| Other Prepaid Expense Current | $1.0M | $657.0K | $1.0M | $733.0K | $530.0K | $422.0K | ||||||||||
| Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares | 2.0M | 2.4M | 5.5M | 7.7M | ||||||||||||
| Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent | 2.4M | 1.6M | 2.0M | 2.1M | 1.5M | |||||||||||
| Prepaid Expense Current | $122.2K | $215.9K | $317.2K | $531.2K | ||||||||||||
| Stock Issued During Period Value New Issues | $5.1M | $5.4M | $25.0K |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.